Susan Podlogar
Human Resources Officer chez METLIFE, INC.
Fortune : 7 M $ au 31/03/2024
Profil
Susan M.
Podlogar is currently a Director at MetLife Foundation, a Director at Tevogen Bio Holdings, Inc., and the Chief Human Resources Officer & Executive VP at MetLife, Inc. She previously worked as a Director at Tevogen Bio, Inc., Vice President-Human Resources at Johnson & Johnson, Inc., and Trustee at State Theatre New Jersey.
Ms. Podlogar holds an MBA degree from the University of South Florida and an undergraduate degree from the University of Wisconsin Parkside.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
METLIFE, INC.
0,01% | 01/03/2024 | 79 794 ( 0,01% ) | 6 M $ | 31/03/2024 |
0,12% | 14/02/2024 | 193 923 ( 0,12% ) | 727 211 $ | 31/03/2024 |
Postes actifs de Susan Podlogar
| Sociétés | Poste | Début |
|---|---|---|
| METLIFE, INC. | Human Resources Officer | 10/07/2017 |
| MetLife Foundation | Director/Board Member | - |
Anciens postes connus de Susan Podlogar
| Sociétés | Poste | Fin |
|---|---|---|
Johnson & Johnson, Inc.
 Johnson & Johnson, Inc. Insurance Brokers/ServicesFinance Johnson & Johnson, Inc. provides insurance brokerage services. The company was founded in 1930 and is headquartered in Mount Pleasant, SC. | Corporate Officer/Principal | 01/06/2017 |
| State Theatre New Jersey | Director/Board Member | 01/01/2017 |
Tevogen Bio, Inc.
 Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Director/Board Member | - |
Formation de Susan Podlogar
| University of South Florida | Masters Business Admin |
| University of Wisconsin Parkside | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| METLIFE, INC. | Finance |
| Entreprise privées | 4 |
|---|---|
| MetLife Foundation | |
Johnson & Johnson, Inc.
Johnson & Johnson, Inc. Insurance Brokers/ServicesFinance Johnson & Johnson, Inc. provides insurance brokerage services. The company was founded in 1930 and is headquartered in Mount Pleasant, SC. | Finance |
| State Theatre New Jersey | |
Tevogen Bio, Inc.
Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
